8-K: Liquidia Loses Lawsuit Against FDA and United Therapeutics Over Tyvaso DPI Exclusivity

Liquidia Corporation's lawsuit challenging the FDA's decision to grant regulatory exclusivity to United Therapeutics' Tyvaso DPI was unsuccessful, as the District Court ruled in favor of the FDA and United Therapeutics.

Summary

• Liquidia Corporation filed a lawsuit against the FDA in the U.S. District Court of the District of Columbia on August 21, 2024, challenging the FDA's decision to grant 3-year new clinical investigation exclusivity to Tyvaso DPI.
• A summary judgment hearing was held on December 5, 2024.
• On February 27, 2025, the District Court denied Liquidia's motion for summary judgment and granted the motions for summary judgment filed by the FDA and United Therapeutics, affirming the FDA's award of regulatory exclusivity to Tyvaso DPI.
• The regulatory exclusivity for Tyvaso DPI will still expire on May 23, 2025.
• United Therapeutics also filed a cross claim challenging the FDA's acceptance of Liquidia's amended New Drug Application (NDA) for review, and Liquidia intervened in the cross claim on November 5, 2024.
• Motions to dismiss United Therapeutics' cross claim, filed by Liquidia and the FDA, remain pending with the District Court.

Sentiment

Score: 3

Explanation: The document reports a legal loss for Liquidia, which is a negative development. The pending cross claim adds further uncertainty. The sentiment is therefore negative.

Negatives

• Liquidia lost the lawsuit against the FDA and United Therapeutics, failing to overturn the regulatory exclusivity granted to Tyvaso DPI.
• The District Court's decision affirms the FDA's award of regulatory exclusivity to Tyvaso DPI.

Risks

• The pending cross claim by United Therapeutics against the FDA's acceptance of Liquidia's NDA introduces uncertainty.
• The loss of the lawsuit could impact Liquidia's competitive position regarding inhaled treprostinil products.

Future Outlook

The company will continue to pursue its motion to dismiss United Therapeutics' cross claim.

Industry Context

This legal decision impacts the competitive landscape for inhaled treprostinil products, particularly concerning market exclusivity.

Legal Proceedings

• Liquidia filed a lawsuit against the FDA and United Therapeutics regarding Tyvaso DPI regulatory exclusivity, which it lost.
• United Therapeutics filed a cross claim challenging the FDA's acceptance of Liquidia's NDA, which is still pending.

Stakeholder Impact

• Shareholders may react negatively to the news of the legal loss.
• The outcome could affect Liquidia's competitive position and future revenue potential.

Next Steps

• Liquidia will continue to pursue its motion to dismiss United Therapeutics' cross claim.

Key Dates